News | November 18, 2013

Boston Scientific Announces First Commercial Implants of Lotus Valve System in Europe

Patients in Germany receive TAVI devices designed for total control, accurate deployment

heart valve repair hybrid or TAVI boston scientific lotus aortic repair system
November 18, 2013 — The first two commercial implants of the Boston Scientific Lotus Valve System have taken place in a German hospital. Gerhard Schuler, M.D. and professor, University of Leipzig, Leipzig, Germany and Axel Linke M.D. and professor Leipzig, led the procedures at the Heart Center — University Hospital Leipzig. CE mark approval for the Lotus Valve System was announced Oct. 28 at the Transcatheter Cardiovascular Therapeutics conference (TCT 2013) in San Francisco.
The Lotus Valve System offers an alternative treatment for patients with severe aortic stenosis at high risk of surgical valve replacement. It is a transcatheter aortic valve implantation (TAVI) device designed to give physicians total control throughout the TAVI procedure. The Lotus Valve is comprised of bovine pericardium and a nitinol frame with a central marker to aid in precise positioning. It features a novel Adaptive Seal technology to help minimize aortic regurgitation. It is also the first device of its kind that can be fully retrieved, redeployed or repositioned, even after full valve deployment and prior to release. 
"The Lotus Valve System permits very precise positioning of the device and the Adaptive Seal minimizes potential paravalvular leakage," said Schuler.  "These are the key differentiating features of this new technology."
Ian Meredith Ph.D., director, MonashHeart at Monash Medical Centre, Melbourne, Australia and principal investigator presented the primary endpoint data from the REPRISE II clinical trial at TCT 2013. The data demonstrated that the Lotus Valve System was successfully implanted and correctly positioned in all 120 patients, and met the co-primary endpoints of mean aortic valve pressure gradient and all-cause mortality at 30 days. The valve produced impressive clinical results with no valve malpositioning, migration or severe embolization, low clinical event rates that were consistent with those reported for other valves and negligible paravalvular aortic regurgitation at 30 days.
The Lotus Valve System comes pre-attached on a transfemoral delivery system and is inserted into the body through a small incision in the leg.  Once delivered across the diseased aortic valve, the Lotus Valve System is deployed through a controlled mechanical expansion that is distinct from balloon-expandable or self-expanding valves.
"The controlled mechanical expansion and early functioning of the valve facilitate precise positioning on the first attempt, and the ability to fully or partially recapture the valve, if necessary, provides additional assurance that the valve will be ideally positioned at the end of the procedure," said Linke. 
The Lotus Valve System is available at select centers in Europe with commercial site expansion accelerating as physicians and centers become fully trained. The valve is available in a 23 and 27 mm size, treating patients with aortic annulus sizes from 20 to 27 mm. The Lotus Valve System is an investigational device in the United States and Japan and is not available for sale.
"Completing our first commercial implants marks a key step forward in offering an advanced new technology in Europe,” said Tom Fleming, vice president and general manager, structural heart, Boston Scientific.” The Lotus Valve System has been designed to give the physician increased control during implantation and to help provide a more precise, predictable procedure. We believe the Lotus Valve is an important treatment alternative for severe aortic valve disease patients at high risk for surgical valve replacement."
For more information:

Related Content

Videos | Heart Valve Technology | March 15, 2018
Insights from the STS/ACC TVT Transcatheter Valve Registry, presented at the American College of Cardiology (ACC) 201
CoreValve TAVR System Shows Strong Long-Term Performance in Clinical Trials
News | Heart Valve Technology | March 12, 2018
Medtronic plc unveiled outcomes from the CoreValve U.S. Pivotal Extreme Risk Study and the real-world NOTION trial (...
The U.S. Food and Drug Administration expanded the approval of a heart valve to include a size small enough to be used in newborn pediatric patients to treat heart defects.
News | Heart Valve Technology | March 07, 2018
The U.S. Food and Drug Administration expanded the approval of a heart valve to include a size small enough to be used...
Videos | Heart Valve Technology | March 02, 2018
Sammy Elmariah, M.D., MPH, interventional structural heart disease, Massachusetts General Hospital, discusses the pro
Boston Scientific Projects 2019 Launch for Lotus Edge Aortic Valve System
News | Heart Valve Technology | February 23, 2018
February 23, 2018 — Boston Scientific announced In November 2017 a delay to timelines for commercialization of the Lo
Gate Bioprosthesis Used in Canada's First Transcatheter Valve Replacement for Tricuspid Regurgitation
News | Heart Valve Technology | February 22, 2018
NaviGate Cardiac Structures Inc. (NCSI)announced that on Feb. 2, 2018, its catheter-guided Gate valved-stent...
Edwards Lifesciences Centera self expanding transcatheter (TAVR) valve has been approved with CE mark for use in Europe.
Feature | Heart Valve Technology | February 15, 2018
February 15, 2018 — Edwards Lifesciences Corp.
Boston Scientific Enters Investment and Acquisition Option Agreement With Millipede
News | Heart Valve Technology | January 24, 2018
Boston Scientific Corp. announced it has closed an investment and entered into an acquisition option agreement with...
Edwards LifeSciences Recalls Sapien 3 Certitude Delivery System
News | Heart Valve Technology | January 11, 2018
The U.S. Food and Drug Administration (FDA) announced that Edwards LifeSciences is recalling its Certitude Delivery...
Videos | Heart Valve Technology | January 04, 2018
Adam Greenbaum, M.D., co-director, Center for Structural Heart Disease, Henry Ford Hospital, Detroit, explains how hi
Overlay Init